| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3f1ea44a9ee565d76ff3245aae36e95f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e92ad142ec6fbbd91093425fb1bcab8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 |
| filingDate |
2012-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa31f262ec856e757c747d42d8447c1e |
| publicationDate |
2014-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8653090-B2 |
| titleOfInvention |
Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents |
| abstract |
A composition and method for the treatment of the side-effects associated with the administration of cancer chemotherapeutic agents involves the oral ingestion of a slow release capsule containing adenine and orotate. The administration of a protein pump inhibitor decreases systemic absorption of orotate and the administration of allopurinol decreases the formation of 2,8-dihydroxy adenine from adenine. In an alternative embodiment, cationic liposomes contain purine/pyrimidine precursors. The cationic liposomes bind to the cells lining the mucosa of the intestinal tract and then the contents of the cationic liposome are then taken up in the interior of the cells to prevent the metabolism of the cancer treatment drug 5-FU into a toxic species. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11337631-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10736557-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9119855-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014134239-A1 |
| priorityDate |
2008-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |